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Background and Objectives A photochemical treatment process (PCT) utilizing
amotosalen and UVA light (INTERCEPTTM Blood System) has been developed for
inactivation of viruses, bacteria, parasites and leucocytes that can contaminate
blood components intended for transfusion. The objective of this study was to
further characterize the safety profile of INTERCEPT-treated platelet components
(PCT-PLT) administered across a broad patient population.
Materials and Methods This open-label, observational haemovigilance pro-
gramme of PCT-PLT transfusions was conducted in 21 centres in 11 countries.
All transfusions were monitored for adverse events within 24 h post-transfusion
and for serious adverse events (SAEs) up to 7 days post-transfusion. All adverse
events were assessed for severity (Grade 0–4), and causal relationship to PCT-PLT
transfusion.
Results Over the course of 7 years in the study centres, 4067 patients received
19 175 PCT-PLT transfusions. Adverse events were infrequent, and most were of
Grade 1 severity. On a per-transfusion basis, 123 (06%) were classified an acute
transfusion reaction (ATR) defined as an adverse event related to the transfusion.
Among these ATRs, the most common were chills (77, 04%) and urticaria (41,
02%). Fourteen SAEs were reported, of which 2 were attributed to platelet trans-
fusion (<01%). No case of transfusion-related acute lung injury, transfusion-
associated graft-versus-host disease, transfusion-transmitted infection or death
was attributed to the transfusion of PCT-PLT.
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Conclusion This longitudinal haemovigilance safety programme to monitor PCT-
PLT transfusions demonstrated a low rate of ATRs, and a safety profile consistent
with that previously reported for conventional platelet components.
Key words: amotosalen, haemovigilance, INTERCEPT, pathogen inactivation,
platelets, safety.
Introduction
Since 2002, the INTERCEPTTM Blood System for platelets
(Cerus Corporation BV, Amersfoort, the Netherlands), a
PCT process that inactivates viruses, bacteria, protozoa
and leucocytes potentially contaminating PLT compo-
nents with amotosalen and low-energy UVA, has been
approved for use in Europe through CE Mark registration.
Blood centres in Belgium, Italy, Norway and Spain
implemented routine production of PCT-PLT in 2003.
Adoption of PCT-PLT components has expanded since
then and is currently in routine clinical use in more than
100 blood centres in 20 countries. As of September 2014,
over 123 million PCT-PLTs have been produced for
transfusion to patients.
Postmarketing haemovigilance (HV) programmes
that monitor adverse events during routine clinical
use extend the safety characterization of new prod-
ucts or technologies. HV studies include a greater
number and wider demographic spectrum of patients
than are feasible in randomized controlled trials [1–3]
and provide additional data about the safety profile
of these products. The World Health Organization has
issued a recommendation for HV programmes specifi-
cally in the field of blood transfusion safety to ‘iden-
tify and prevent occurrence or recurrence of
transfusion-related unwanted events’ [4]. The Euro-
pean Haemovigilance Network also recommends sur-
veillance for AEs after transfusion of labile blood
components [5–7].
After centres began routine production of PCT-PLT,
Cerus implemented an Internet-based, active HV pro-
gramme to prospectively collect additional safety
information. In this study, each PCT-PLT transfusion
was reported and documented regardless of whether
an AE occurred or not. This HV system was largely
modelled after the French HV system for documenta-
tion of recipient transfusion incidents [8]. The
PCT-PLT HV experience has been partially reported
previously in two interim reports [9, 10]. This account
provides an aggregate analysis of all 19 175 PCT-PLT
transfusions occurring under the HV programme
to date and includes data for 6632 additional
transfusions.
Materials and methods
Study design
This was a prospective, non-randomized, one-arm, obser-
vational, HV study documenting all transfused PCT-PLT
components (Table 1) in participating centres. Data pre-
sented here represent the total HV experience from three
studies: HV1 [10], HV2 [9] and HV3 from inception in
October 2003 to December 2010. The objective of the
study was to determine the proportion of transfusions
associated with an acute transfusion reaction (ATR) fol-
lowing administration of PCT-PLT. There were no ran-
domization requirements, no inclusion criteria other than
the need for PLT transfusion and no exclusion criteria of
patients.
The study was conducted in accordance with the
European regulations governing clinical investigations
of medical devices and the International Conference on
Harmonization Guideline for Good Clinical Practice E6
(CPMP/ICH/135/95). No ethical committee approval or
patient consent was required as the system is a
CE-marked Class III medical device approved for sale in
the European Union, and the study was conducted
under existing HV programmes in compliance with
country law to monitor the impact of new technologies
on blood transfusion practice. Patients received transfu-
sions of PCT-PLT components according to the standard
institutional practice. Patient confidentiality was pre-
served through assignment of a centre-specific study
number, and sponsor did not have access to any
patient files.
Study report forms
Participating centres used a standardized data capture
form to record patient characteristics, primary diagnosis,
indication for transfusion and clinical observations of
AEs [10]. The data collection form was designed based on
HV report forms already in use in Europe [11]. A data
and safety monitoring board (DSMB) approved the HV
report form before utilization and provided oversight of
the study. Trained HV personnel from the blood centres
recorded patient characteristics and demographics,
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platelet component characteristics, transfusion events and
AE documentation following the transfusion.
A checklist format was used to capture clinical AE
symptoms and signs for each transfusion. The checklist
documented the presence of fever, chills, cardiac arrhyth-
mia, hypotension, pruritus, urticaria, skin rash, jaundice,
pulmonary oedema, bronchospasm, dyspnoea, tachycar-
dia, respiratory distress, nausea, vomiting, lower back
pain, chest pain, abdominal pain and shock. AEs not
listed on the checklist, such as refractoriness to platelet
transfusion, hypertension, cephalea, pain in the leg, flush,
malaise, cyanosis, oxygen desaturation, volume overload
and transfusion-related acute lung injury (TRALI), were
also recorded. Standardized criteria were used to define
transfusion-related sepsis, TRALI [12], transfusion-
associated circulatory overload (TACO) and transfusion-
associated graft-versus-host disease (TA-GVHD).
Safety monitoring
Patients who received PCT-PLT were monitored for any
AE with each transfusion. All AEs within the first 24 h
and all serious adverse events (SAEs) within 7 days fol-
lowing each transfusion were recorded.
If an AE occurred after transfusion, additional clinical
and biological information was collected to allow diagno-
sis and assessment of causality and severity. AEs were
graded using a 0–4 numerical scale from least to most
severe [13]: Grade 0: isolated dysfunction without clinical
or biological manifestation; Grade 1: absence of
immediate or long-term life-threatening effects; Grade 2:
long-term life-threatening effects; Grade 3: immediate
life-threatening effects; and Grade 4: death.
The clinical investigator at each site independently
assessed the relationship of each AE to the preceding
PCT-PLT transfusion. An ATR was defined as an AE pos-
sibly related, probably related or related to a PCT-PLT
transfusion. SAEs (Grade 2–4 reactions) were reported in
greater detail with a narrative for each event. All reported
SAEs were reviewed by the appropriate national regula-
tory authority and by the Cerus Drug Safety Officer.
If an AE was reported, temperature, blood pressure and
heart rate were recorded. Abnormal clinical laboratory
values, results of diagnostic procedures (chest radiograph)
and bacterial cultures from patients and blood compo-
nent sources were documented on the report form when
considered by the physician to be associated with an
ATR.
Preparation of test materials
PLTs were collected by apheresis or prepared from
whole-blood-derived buffy-coat concentrates according to
each centre’s standard operating procedures. Briefly, vol-
unteer donors were screened and tested for transfusion-
transmitted pathogens according to each centre’s
procedures, and in compliance with relevant national
regulations. All components were leucocyte reduced,
Table 1 INTERCEPT haemovigilance study
centres Country Transfusion centre Number of platelet transfusions
Belgium Mont Godinne 7551
Belgium Erasme 899
Belgium Brugge 440
Czech Republic Prague 4
Germany L€ubeck 77
France Strasbourg 2048
France St Etienne 854
France Rennes 501
France La Reunion 1950
Iceland Reykjavik 354
Italy Pescara 2
Italy Rome 794
Norway Bergen 634
Norway Trondheim 139
Portugal Lisbon 102
Slovenia Ljubljana 540
Spain Madrid RC 382
Spain Leon 381
Spain Barcelona 356
Spain Santiago de Compostela 163
Sweden Uppsala 1004
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either by filtration (SepacellTM PLS-5A; Asahi Biomedical,
Tokyo, Japan; LRP6; Pall Medical, Portsmouth, UK) or
process leucodepletion (Amicus Cell Separator, Fenwal, La
Chatre, France, Haemonetics MCS+, Haemonetics, Brain-
tree, MA, USA, or Trima, Terumo BCT, Lakewood, CO,
USA). Collections containing 25–60 9 1011 PLTs were
suspended in approximately 35% plasma and 65% Inter-
SolTM (Fenwal, Fresenius-Kabi, Lake Zurich, IL, USA) and
treated with amotosalen (nominal final concentration
150 lM) and 3 J/cm2 UVA (320–400 nm) according to
manufacturer’s instructions for use. After treatment, PCT-
PLTs were stored up to 5 or 7 days under temperature-
controlled conditions (22 – 2°C) before release for trans-
fusion. For HV1, PCT-PLTs were transfused before the
expiration period of 5 days. For HV2 and HV3, PCT-PLTs
were transfused prior to 5 or 7 day storage depending
upon regulations of each country.
Statistical analyses
Data were summarized descriptively by mean, standard
deviation, median and range (minimum, maximum) for
continuous data or by frequencies and percentages for
categorical data, using SAS version 9.3 (SAS Institute,
Cary, NC, USA). All PCT-PLT transfusions administered to
a patient were included in the full analysis population,
and data were summarized on a per-transfusion basis and
a per-patient basis. P values for ATR and SAE rates were
calculated utilizing the two-sided Fisher’s exact test.
The primary assessment of safety was the proportion of
PCT-PLT transfusions associated with an ATR. Addition-
ally, patient demographics, primary indication for transfu-
sion, the number of PCT-PLT transfusions received, the
characteristics of the PCT-PLT transfused, the AEs reported
and the time to first reaction were summarized to charac-
terize the safety profile of PCT-PLT. Among patients with
at least one AE reported, the number of transfusions
received before the first occurrence was also summarized.
Results
The study population from the culmination of three active
HV programmes conducted from October 2003 to Decem-
ber 2010 provided a cohort of 4067 patients transfused
with 19 175 PCT-PLT components. Of those, 2016
patients receiving 6632 PCT-PLT transfusions have not
been previously reported. The geographic distribution of
transfusions is presented (Table 1).
Patient characteristics
The majority of the patient population was male (60%;
Table 2). The mean age of the combined cohort was
567 years of age (range <1–96) with 94% of patients
greater than 18 years of age. The diagnostic indication
for platelet transfusion was a haematology disorder
(501%), or intra- or peri-operative support during sur-
gery (175%). Diagnoses other than these accounted for
32% of patients. Of patients being treated for a haematol-
ogy disorder, 424% were receiving conventional chemo-
therapy and 118% received a hematopoietic stem cell
transplant (HSCT). The diagnosis was not specified for 19
patients (05%).
In the study population, 618% had received a blood
product prior to the first PCT-PLT transfusion. Among
these patients, 51% had a history of a transfusion reac-
tion. PCT-PLT transfusions occurred mainly in non-inten-
sive care, inpatient hospital settings. The remaining
transfusions were administered in the intensive care unit
or in outpatient clinics (Table 2).
Platelet component characteristics
There was a shift over time in the PLT production method
used in the participating centres from apheresis collec-
tions to whole-blood buffy-coat extraction (Table 3). The
majority of centres (97%) elected to use PCT-PLT without
c-irradiation for patients at risk of TA-GVHD based on
reported data showing that INTERCEPT effectively inacti-
vates T cells [14]. Additionally, only 19% of the units
were human leucocyte antigen (HLA) matched (Table 3).
Number of transfusions per-patient
Approximately 56% of patients received multiple transfu-
sions of PCT-PLT during the study. The mean number of
transfusions received for each patient for the entire
cohort was 47 (range 1–156) (Table 4). Of the 4067
patients, 441% received only one PCT-PLT transfusion,
279% patients received two to three transfusions, and
281% patients received four or more transfusions. Plate-
let usage was greater for patients diagnosed with haema-
tologic disease where the mean number of transfusions
per patient was 70 (Table 4).
AEs and ATRs following PCT-PLT transfusion
On a per-patient basis, the proportion of patients who
experienced any AE, regardless of the grade or cause, was
31% (126/4067 patients; Table 5). Of these, 94 patients
(23% of study population) were classified with an ATR
possibly related, probably related or related to PCT-PLT
transfusion. Only 13 patients (03%) were classified with a
SAE; however, all but 2 were judged as unrelated to PCT-
PLT and assigned alternative causes for the signs and
symptoms by the investigators. No cases of TRALI,
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TA-GVHD and no deaths due to PCT-PLT transfusions
were reported. Additionally, consistent with the rationale
for pathogen reduction, no transfusion-transmitted infec-
tion occurred.
On a per-transfusion basis, 167 of 19 175 transfusions
resulted in an AE (09%). Of those, 123 transfusions (06%)
were classified as ATRs. Only 14 transfusions (01%)
resulted in SAEs, of which 2 (<01%) were classified as
ATRs attributed to PCT-PLTs.
Patients with primary haematological disease
(n = 2038) demonstrated a greater probability of ATRs
(43%, P < 0001) than found for the rest of the cohort.
However, the rate of SAE experienced by this population
was the same (03%). Interestingly, cardiovascular surgery
Table 3 PCT-PLT component characteristics
HV study Patients Transfusion episodes % Buffy coat % Apheresis % c-Irradiated % HLA matched
HV1 [10] 651 5106 80 920 27 31
HV2 [9] 1400 7437 352 648 11 25
HV3 2016 6632 588 412 53 03
Total 4067 19 175 361 639 30 19
HLA, human leucocyte antigen; HV, haemovigilance.
Table 2 Patient and transfusion demographics
Per-patient basis (N = 4067) Per-transfusion basis (N = 19 175)
Sex
Male 2441 (600%) 11 467 (598%)
Female 1622 (399%) 7703 (402%)
Unknown 4 (01%) 5 (<01%)
Age (years)
Mean (SD) 567 (199)
Median 61
Minimum–Maximum 0–96
Location of transfusion
Intensive care unit 2835 (148%)
Outpatient 1164 (61%)
Regular ward 15 170 (791%)
Unknown 6 (<01%)
Haematology–Oncology patients 2038 (501%) 14 349 (748%)
Conventional chemotherapy 1725 (424%) 11 898 (620%)
Stem cell Transplant 478 (118%) 3231 (169%)
Surgery patients 710 (175%) 1317 (69%)
Cardiovascular surgery 593 (146%) 1025 (53%)
Solid organ transplantation 79 (19%) 192 (10%)
Other diagnosis 1300 (320%) 2856 (149%)
Missing diagnosis 19 (05%) 653 (34%)
History of a previous transfusion
Yes 2512 (618%) 12 771 (666%)
No 1176 (289%) 5308 (277%)
Unknown 378 (93%) 1095 (57%)
Missing 1 (<01%) 1 (<01%)
If history of previous transfusion – did they experience an ATR?
Yes 127 (51%) 1338 (105%)
No 2272 (904%) 11 078 (867%)
Unknown 112 (45%) 352 (28%)
Missing 1 (<01%) 3 (<01%)
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patients (n = 593) experienced a lower ATR rate (03%,
P < 0001) and a similar SAE rate (05%, P = 0421) com-
pared to the rest of the patient population.
Paediatric patients (n = 242) experienced a similar ATR
rate (37%, P = 0179) and SAE rate (04%, P = 0550)
when compared with adults. No paediatric patient
experienced an SAE judged to be related to PCT-PLT.
Additionally, the number of PLT transfusions per patient
received by paediatric patients was similar to the total
study population (Table 4). No AEs occurred in neonate
patients under 28 days old (n = 46).
Characteristic of clinical signs and symptoms
associated with ATRs
The most common clinical characteristics of ATRs per-
patient were chills (15%) and urticaria (09%) (Table 5).
The other reported ATRs were reported in 06% or less of
patients for each symptom (Table 5). The symptoms
observed, their frequencies and the clinical severities were
similar in this study as to those reported for conventional
PLT [15–23]. Most ATRs were described by investigators
as Grade 1 in severity.
On a per-transfusion basis, the most frequently
observed ATR symptom was chills reported for 77 of
19 175 transfusions (04%). Urticaria was observed after
02% of transfusions. Additional signs and symptoms
were present with 01% or less of transfusions
(Table 5).
Cardiac and respiratory events
The subset of AEs specific to the system order class for
cardiac disorders and respiratory, thoracic and mediasti-
nal disorders were summarized (Table 5). There were 10
transfusion recipients with cardiac disorder AEs: seven
were tachycardia (02%) and three were cardiac arrhyth-
mia (<01%). The majority of these events were Grade 1
in severity, and consistent with reported observations in
transfusion recipients. Adverse events in the respiratory,
thoracic and mediastinal disorders categories were present
in 22 patients (05%) and were most frequently due to
dyspnoea (19 patients) (Table 5). Respiratory distress was
observed in three patients (<01%), and there was 1 case
(<01%) of bronchospasm. No cases of TRALI or anaphy-
laxis were reported for haematology–oncology patients
within the period of observation despite repeated expo-
sure to PCT-PLT.
Further analysis of the reported AEs in the cardiac and
respiratory system organ class revealed classification of
six cardiac events (01% of patients) and 13 respiratory
events (03% of patients) as ATRs, the majority of which
were Grade 1 (Table 5). Of these, 5 were cases of tachy-
cardia, 1 was a case of arrhythmia, 12 were cases of
dyspnoea, and one was a case of bronchospasm.
SAE following platelet transfusion
During the course of the programmes, a total of 13
patients (03%) experienced AEs classified as SAEs.
Eleven of the 13 SAEs were assessed to be ‘unrelated or
probably unrelated’ to the PCT-PLT transfusion and were
attributed to the progression of underlying disease. The
remaining 2 SAE were described by the investigator as
‘possibly related’ to the PCT-PLT transfusion.
Table 4 Number of transfusion episodes per-patient groupa
Number of transfusions Per-patient basis
Total patient population (n = 4067)
Mean (SD) 47 (99)
Median 2
Minimum–Maximum 1–156
1 1794 (441%)
2 804 (198%)
3 328 (81%)
≥4 1141 (281%)
Paediatric patients (n = 242)
Mean (SD) 46 (84%)
Median 2
Minimum–Maximum 1–66
1 109 (450%)
2 49 (202%)
3 16 (66%)
≥4 68 (281%)
Neonate patients (n = 46)
Mean (SD) 20 (20)
Median 1
Minimum–Maximum 1–9
1 31 (674%)
2 8 (174%)
≥4 7 (152%)
Haematology–Oncology patients (n = 2038)
Mean (SD) 70 (131)
Median 3
Minimum–Maximum 1–156
1 649 (318%)
2 346 (170%)
3 190 (93%)
≥4 853 (419%)
Cardiovascular patients (n = 593)
Mean (SD) 17 (17)
Median 1
Minimum–Maximum 1–24
1 391 (659%)
2 116 (196%)
3 34 (57%)
≥4 52 (88%)
aOne transfusion episode is equivalent to one PCT-PLT component.
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Patient 01-464 developed a haemorrhage during mitral
valve surgery and was treated with PCT-PLT and methy-
lene blue-treated fresh frozen plasma. He experienced
hypotension after the second study transfusion. One day
later, the patient experienced a second hypotensive event
after receiving a red blood cell transfusion. The investiga-
tor attributed the event as an allergic adverse event
related to the PLT transfusion. The patient recovered and
was released.
Patient 1868 had a history of aortic valve replace-
ment and bypass. The patient experienced urticaria,
bronchospasm, hypotension and chest/abdominal pain
after a single transfusion of PCT-PLT and required
mechanical ventilation. The patient recovered the same
day, and the bacterial culture of the platelet container
was negative. No device malfunctions were reported
during the preparation of the PLTs, and the patient did
not receive any additional transfusions. The investigator
considered the events ‘possibly related’ to the PCT-PLT
transfusion.
Number of transfusions prior to the first AE
Among the 126 patients who experienced at least one AE,
repeated exposure to PCT-PLT did not appear to increase
the likelihood of a transfusion reaction (Table 6). The mean
number of transfusions before first AE occurrence was 83.
Discussion
This active HV programme prospectively monitored rou-
tine transfusions of 19 175 PCT-PLT components into
4067 recipients. Only 94 patients (23%) experienced an
ATR during the study (Table 5). On a per-transfusion
basis, 123 transfusions (06%) were associated with ATRs
(Table 5). The active design of this HV programme stipu-
lated that all transfusions were evaluated, allowing for a
greater amount of clinical data to be collected for a large
patient population. This approach facilitates the detection
of unexpected or low-grade AEs.
There are several published reports on the frequency of
ATRs for conventional PLTs that can be used as a com-
parison to determine whether use of PCT-PLTs is associ-
ated with an increased risk. Concurrent to this PCT-PLT
HV programme, independent national HV programmes in
France and Switzerland documented their experience with
PLT transfusions [24]. The Agence Francaise de Securite
Sanitaire des Produits de Sante (AFSSAPS), later renamed
Agence Nationale de Securite du Medicament et des
Produits de Sante (ANSM), has published results from an
independent, active HV programme which monitors the
routine use of blood components in France. Between 2009
and 2012, approximately 250 000 conventional PLT
products were transfused each year. ATR frequency was
reported to be 10288 per 20 000 units (05%), 5279 per
100 000 units (05%), 4432 per 100 000 units (04%) and
4061 per 100 000 units (04%) for each year, respectively
[17–20].
Swissmedic, the Swiss Agency for Therapeutic Prod-
ucts, also reported results from an independent HV
surveillance programme on the frequency and severity of
transfusion reactions. In 2008, 155 ATRs were observed
after 27 669 transfusions (06%) [25]. Analysis of the
Table 6 Number of PCT-PLT transfusions per patient prior to the first AE
Number of transfusions before first AE Per-patient basis
Total patient population (n = 4067, 126 AE)
1 37 (091%)
2 16 (039%)
3 8 (020%)
4 9 (022%)
5 5 (012%)
6–10 22 (054%)
11–19 15 (037%)
≥20 14 (034%)
Mean (SD) 83 (146)
Median 4
Minimum–Maximum 1–139
Paediatric patients (n = 242, 13 AE)
1 3 (124%)
2 1 (041%)
4 1 (041%)
6–10 4 (165%)
11–19 2 (083%)
≥20 2 (083%)
Mean (SD) 98 (101)
Median 6
Minimum–Maximum 1–30
Haematology–Oncology patients (n = 2038, 111 AE)
1 26 (128%)
2 14 (069%)
3 8 (039%)
4 9 (044%)
5 5 (025%)
6–10 20 (098%)
11–19 15 (074%)
≥20 14 (069%)
Mean (SD) 92 (153)
Median 4
Minimum–Maximum 1–139
Cardiovascular patients (n = 593, 3 AE)
1 2 (034%)
6–10 1 (017%)
Mean (SD) 27 (29)
Median 1
Minimum–Maximum 1–6
AE, adverse event.
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combined period from 2009 to 2011 documents 223 ATRs
per 66 000 transfusions (03%) [23]. Based on the data
above, there appears to be no increased risk of ATRs after
transfusion of PCT-PLTs vs. conventional PLTs.
The French and Swiss programmes also published the
results of their experience utilizing PCT-PLT components.
The results reported are consistent with the frequency and
type of AEs reported here. The French HV programme
from 2009 to 2010 documents the rates of ATRs related
to PCT-PLT transfusion to be steady at 02% (51 of
21 767 transfusions) and 02% (34 per 21 897 transfu-
sions) for each year, respectively. Swissmedic also
reported their HV experience for the years 2011–2013.
The reported rate of ATRs that were related to PCT-PLT
transfusion was 03% (251 per 95 515 transfusions) [23],
again similar to the results described here.
When patient groups are subdivided by diagnosis, dif-
ferences in ATR rates were observed. The higher ATR rate
observed for patients with haematologic disease may be
attributed to the increased number of transfusions this
population received (Table 4). Similarly, the decreased
ATR rate observed for cardiovascular surgery patients
may be due to decreased platelet usage in these patients
(Table 4). However, importantly the SAE rate for both
these populations was not different than observed for the
overall population.
Since country-specific HV programmes do not report
on a per-patient basis, it is difficult to determine a base-
line rate of transfusion reactions per recipient. Some
available literature includes the Trial to Reduce Alloim-
munization to Platelets (TRAP) study, which examined
the incidence of moderate and severe ATRs in 598
patients with acute myeloid leukaemia receiving 8769
PLT transfusions [16]. The study found that 22% of
patients experienced at least one ATR. For this pro-
gramme, when ATRs were evaluated for only haematolo-
gy–oncology patients, a significantly lower per-patient
(43%) and per-transfusion (08%) ATR rate was observed.
It is thought that the use of platelet additive solution
(PAS) during the preparation of PCT-PLTs may partially
account for the reduction in ATR incidence. The TRAP
study did not utilize PAS during platelet preparation.
Consistent with the suggestion above, a study by
Cazenave et al. [26] found that the AE rate was signifi-
cantly less from transfusions of PLTs prepared with 65%
T-Sol/35% plasma vs. 100% plasma (20% vs. 29%,
P = 00094). The AE rate was reported to decrease to
17% for transfusions additionally treated with PCT
(P = 00214). A recent study by Tobian et al. [27] also
demonstrated that the ATR rate was lower for PLTs
prepared in 65% PASIII/35% plasma than 100% plasma
(10% vs. 18%, respectively). The 604 patients who
received 3884 PLT transfusions suspended in 100%
plasma experienced 72 ATR, while the 345 patients who
received 1194 PLT transfusion containing PASIII experi-
enced only 12 ATR. Therefore, the use of PASIII resulted
in a 46% reduction in ATR.
The absence of reports of TRALI associated with plate-
let transfusion in this HV programme is important in the
view of previous observations in the SPRINT trial of ALI
in approximately 5% of HSCT patients [12]. The haema-
tology–oncology patients enrolled in this HV programme
were repeatedly transfused and observed for all AEs and
SAEs following each transfusion (including respiratory
symptoms) for 7 days. Under these conditions, it appears
highly likely that probable cases of TRALI would be
reported given the intensity of the medical intervention
required to diagnose and treat TRALI. Additionally, a
similar low frequency of TRALI associated with routine
use of PLT components has been observed by the French
HV system. From 2008 to 2011, only 2 (0005%,
n = 82 383 transfusions) cases of TRALI occurred after
PCT-PLT transfusion and 26 (0003%, n = 1 022 224
transfusions) were associated with transfusion of conven-
tional PLTs.
In conclusion, we report the combined 7-year results
of an active HV programme designed to monitor all
PCT-PLT transfusions at participating centres. Incidence
of ATR associated with PCT-PLTs was consistent with
the per-transfusion ATR rates of conventional PLTs and
at the lower range of ATRs reported per-patient. The
clinical experience of 4067 patients receiving 19 175
transfusions has demonstrated that PLT components
treated with amotosalen and UV light for pathogen
reduction were well tolerated in routine clinical
practice.
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